CRISPR-based Electrochemical Biosensor Detects Disease-related MicroRNAs
By LabMedica International staff writers Posted on 03 Dec 2019 |

Image: Researchers introduced the first electrochemical CRISPR-based biosensor to help improve disease diagnostics (Photo courtesy of Richard Bruch, University of Freiburg)
A microfluidic chip containing a CRISPR/Cas-based electrochemical biosensor has been introduced as a device for the rapid and precise analysis of the microRNAs involved in various disease states.
MicroRNAs (miRNAs) and short interfering RNAs (siRNA) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia, and cardiovascular conditions.
CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.
Recent computational efforts to identify new CRISPR systems uncovered a novel type of RNA targeting enzyme, Cas13. The diverse Cas13 family contains at least four known subtypes, including Cas13a (formerly C2c2), Cas13b, Cas13c, and Cas13d. Cas13a was shown to bind and cleave RNA, protecting bacteria from RNA phages and serving as a powerful platform for RNA manipulation. It was suggested that Cas13a could function as part of a versatile, RNA-guided RNA-targeting CRISPR/Cas system holding great potential for precise, robust, and scalable RNA-guided RNA-targeting applications.
Investigators at the University of Freiburg (Germany) exploited the features of Cas13a by using it to power a microfluidic, integrated electrochemical biosensor for the on‐site detection of microRNAs. An RNA-containing serum sample was placed in the sensor. If it contained the target RNA, this molecule combined with a protein complex in the solution and activated the Cas cleavage enzyme. Following activation, the enzyme cleaved reporter RNAs that were attached to signaling molecules, generating an electrical current, which was measured electrochemically. This change indicated whether the target miRNA was present in the sample. If the target microRNA was not present, no current was generated.
The investigators showed that by employing this unique combination of agents, the quantification of the potential microRNA tumor markers miR‐19b and miR‐20a was achieved without nucleic acid amplification. The system required less than 0.6 microliters of sample, had a readout time of nine minutes, and an overall process time of less than four hours. Furthermore, the feasibility of the biosensor platform to detect miR‐19b in serum samples from children suffering from brain cancer, was demonstrated.
“Our electrochemical biosensor is five to 10 times more sensitive than other applications which use CRISPR/Cas for RNA analysis,” said contributing author Dr. Can Dincer, a research group leader in the department of microsystems engineering at the University of Freiburg. “What is special about our system is that it works without the replication of miRNA, because in that case, specialized devices and chemicals would be required. That makes our system low-cost and considerably faster than other techniques or methods.”
The CRISPR-based biosensor was described in the October 30, 2019, online edition of the journal Advanced Materials.
Related Links:
University of Freiburg
MicroRNAs (miRNAs) and short interfering RNAs (siRNA) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia, and cardiovascular conditions.
CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.
Recent computational efforts to identify new CRISPR systems uncovered a novel type of RNA targeting enzyme, Cas13. The diverse Cas13 family contains at least four known subtypes, including Cas13a (formerly C2c2), Cas13b, Cas13c, and Cas13d. Cas13a was shown to bind and cleave RNA, protecting bacteria from RNA phages and serving as a powerful platform for RNA manipulation. It was suggested that Cas13a could function as part of a versatile, RNA-guided RNA-targeting CRISPR/Cas system holding great potential for precise, robust, and scalable RNA-guided RNA-targeting applications.
Investigators at the University of Freiburg (Germany) exploited the features of Cas13a by using it to power a microfluidic, integrated electrochemical biosensor for the on‐site detection of microRNAs. An RNA-containing serum sample was placed in the sensor. If it contained the target RNA, this molecule combined with a protein complex in the solution and activated the Cas cleavage enzyme. Following activation, the enzyme cleaved reporter RNAs that were attached to signaling molecules, generating an electrical current, which was measured electrochemically. This change indicated whether the target miRNA was present in the sample. If the target microRNA was not present, no current was generated.
The investigators showed that by employing this unique combination of agents, the quantification of the potential microRNA tumor markers miR‐19b and miR‐20a was achieved without nucleic acid amplification. The system required less than 0.6 microliters of sample, had a readout time of nine minutes, and an overall process time of less than four hours. Furthermore, the feasibility of the biosensor platform to detect miR‐19b in serum samples from children suffering from brain cancer, was demonstrated.
“Our electrochemical biosensor is five to 10 times more sensitive than other applications which use CRISPR/Cas for RNA analysis,” said contributing author Dr. Can Dincer, a research group leader in the department of microsystems engineering at the University of Freiburg. “What is special about our system is that it works without the replication of miRNA, because in that case, specialized devices and chemicals would be required. That makes our system low-cost and considerably faster than other techniques or methods.”
The CRISPR-based biosensor was described in the October 30, 2019, online edition of the journal Advanced Materials.
Related Links:
University of Freiburg
Latest Technology News
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more